Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine challenge on brain glutamate release
NCT06432322Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Jun 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in treatment-resistant depression (TRD) comparing Esketamine with Placebo (2 arms). Primary endpoint: Brain Glutamate Dynamic Change. Started Jun 2024; status: completed.
02
Drugs
esketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT06432322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06432322.